Life Science Update | October 2025
USPTO, JPO, and EPO Meet to Discuss Global IP Challenges Joseph Mallon, Ph.D. & Ashley C. Morales Beginning on October 20, 2025, recently confirmed United States Patent and Trademark Office (USPTO) Director...
AI and the Fight Against Antimicrobial Resistance
Antimicrobial resistance has become a major concern in recent years. According to studies, approximately 1.1 million deaths each year are linked to bacterial resistance to antimicrobial drugs.[1] The fear of...
Keeping PACE With CRISPR
AGILENT TECHNOLOGIES, INC. v. SYNTHEGO CORP. Before Prost, Linn, and Reyna. Appeal from the Patent Trial and Appeal Board. Summary: Obviousness does not require all claimed limitations to be expressly...
Executive Order 14297 and the Global Drug Market: Policy, Pricing, and Uncertainty
On May 12, 2025, President Trump issued Executive Order 14297[1] targeting prescription drug prices in America. The stated purpose of this order is to combat high drug prices in the...
Suspension of the Climate Change Mitigation Pilot Program: What Happens Now?
Effective January 28, 2025, the new administration suspended the Climate Change Mitigation Pilot Program (CCMPP) at the United States Patent and Trademark Office (USPTO).[1] The USPTO had instituted this program...
Renewed Efforts in Congress for Pharmaceutical Patent Reform
With the recent convocation of the 119th Congress, a change in administration, and resignation of USPTO Director Vidal, pharmaceutical patent reform is likely on the minds of many in Washington....
